Neuren Pharmaceuticals (ASX: NEU) has reported that its partner Acadia Pharmaceuticals projects DAYBUE global net sales to reach approximately US$700 million in 2028. This represents more than doubling of revenue from US$348 million in 2024, signalling accelerating commercial momentum for the only FDA-approved treatment for Rett syndrome.
The projections were disclosed during Acadia’s presentation at the 44th annual J.P. Morgan Healthcare Conference. Since its US launch in 2023, more than 2,000 Rett syndrome patients have been treated with DAYBUE, with 12-month persistency now reaching 55%.
What are Neuren’s DAYBUE sales projections for 2028?
Acadia Pharmaceuticals projects DAYBUE global net sales will reach approximately US$700 million by 2028. This trajectory demonstrates sustained commercial growth, with revenue expected to increase from US$348 million in 2024 to US$385 million in 2025 (Acadia guidance), before accelerating to the US$700 million target three years later.
The growth path represents a compound annual expansion in a market where DAYBUE holds exclusive positioning as the first and only approved therapy for Rett syndrome. For Neuren shareholders, this sales trajectory directly impacts royalty revenue streams from the exclusive worldwide licence granted to Acadia.
| Period | Global Net Sales (US$m) |
|---|---|
| CY2023 (Apr-Dec) | 177 |
| CY2024 | 348 |
| CY2025 (Acadia Guidance) | 385 |
| 2028 (Acadia Projection) | ~700 |
The compounding revenue growth reflects market penetration in a patient population that has expanded to approximately 6,000 diagnosed cases in the US, up from the previously estimated range of 5,500 to 5,800 patients. This 30% increase since launch indicates both improved diagnosis rates and growing clinical awareness.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
Three Growth Drivers Behind the US$700 Million Target
Acadia identified three distinct catalysts supporting the US$700 million sales projection for 2028, providing investors with multiple levers for revenue expansion rather than dependence on a single variable.
1. DAYBUE STIX Launch
The FDA approved DAYBUE STIX in December 2025, introducing a powder formulation that addresses practical concerns families and caregivers had with the original liquid format. The product is rolling out on a limited basis in Q1 2026, with full availability expected by beginning of Q2 2026.
This formulation addresses a documented barrier to treatment initiation and adherence. Acadia has indicated the powder format could potentially enable patient growth from families who had previously declined to try or discontinued the liquid formulation. With more than 2,000 patients already treated since launch, recapturing discontinued patients whilst attracting new treatment starts represents a material commercial opportunity.
2. Expanded Commercial Infrastructure
In Q2 2025, Acadia expanded its US customer-facing teams. This infrastructure investment positions the company to reach more prescribing physicians and families, accelerating awareness and adoption in a market where approximately 4,000 diagnosed patients remain untreated.
The expansion follows demonstrated commercial traction, with 12-month persistency improving to 55%. This metric suggests patients and physicians are seeing sufficient benefit to maintain therapy beyond initial trial periods.
3. International Expansion
Geographic diversification is progressing across three key markets. Israel’s Ministry of Health has approved DAYBUE oral solution. In Europe, a Committee for Medicinal Products for Human Use (CHMP) opinion is anticipated in Q1 2026. Japan’s Phase 3 clinical trial of trofinetide is ongoing, with top-line data expected between Q4 2026 and Q1 2027.
These international approvals create multiple revenue streams beyond the US market, reducing geographic concentration risk whilst accessing broader patient populations. European and Japanese regulatory progress provides visibility on near-term catalysts that could accelerate the path to US$700 million in global sales.
How is DAYBUE STIX formulation impacting Rett syndrome treatment?
DAYBUE STIX represents a powder formulation of trofinetide, contrasting with the original liquid format. The FDA approved the product in December 2025, with limited rollout commencing in Q1 2026 and full availability by beginning of Q2 2026.
The powder format addresses practical challenges families and caregivers faced with liquid administration, particularly relevant in paediatric populations where treatment adherence can be influenced by ease of use. Acadia has stated the formulation could potentially enable patient growth from families who had previously declined to try or discontinued the liquid version.
With more than 2,000 Rett syndrome patients treated since US launch, DAYBUE STIX provides an opportunity to recapture discontinued patients whilst reducing barriers for treatment-naive families. The persistency rate of 55% at 12 months suggests improving retention, though the powder formulation may further strengthen this metric.
“DAYBUE STIX powder formulation is now rolling out on a limited basis with full availability by beginning of Q2 2026,” according to Acadia’s presentation. The formulation extends the product lifecycle and competitive positioning of trofinetide, the only FDA-approved treatment for Rett syndrome, whilst maintaining the same active therapeutic agent.
Understanding Rett Syndrome and Market Opportunity
Rett syndrome is a rare neurodevelopmental disorder affecting primarily females, characterised by severe cognitive and physical impairments that emerge in early childhood. DAYBUE (trofinetide) is the first and only FDA-approved treatment for this condition, providing Neuren and Acadia with exclusive market positioning.
The diagnosed US patient population has grown to approximately 6,000, up from the previously estimated range of 5,500 to 5,800 patients. This represents approximately 30% increase since DAYBUE’s launch, indicating improved diagnosis rates and clinical awareness. Despite this growth, more than 2,000 patients have been treated to date, leaving a substantial untreated population.
The 12-month persistency rate of 55% has shown improvement, suggesting patients and physicians are observing meaningful clinical benefit. Over 300 patients are participating in Acadia’s real-world LOTUS study, which continues to generate and publish data supporting clinical utility.
For investors, the expanding diagnosed population combined with low treatment penetration indicates a significant commercial runway. The growing gap between diagnosed patients (6,000) and treated patients (2,000) represents addressable market opportunity, particularly as real-world evidence accumulates and the DAYBUE STIX formulation reduces treatment barriers.
The rarity of Rett syndrome has resulted in both DAYBUE programs and Neuren’s second drug candidate (NNZ-2591) receiving orphan drug designation in the United States and European Union, providing regulatory incentives and market exclusivity periods that protect commercial positioning.
What does DAYBUE’s US$700 million projection mean for Neuren shareholders?
Neuren operates a royalty-based revenue model, having granted an exclusive worldwide licence to Acadia Pharmaceuticals for the development and commercialisation of trofinetide. The US$700 million sales projection represents Acadia’s partner revenue, with Neuren receiving royalties on these sales under the licensing agreement.
This structure provides Neuren shareholders with predictable, high-margin royalty revenue that scales directly with Acadia’s commercial success. As DAYBUE sales grow from US$348 million in 2024 to the projected US$700 million in 2028, Neuren’s royalty income expands proportionally without requiring direct commercialisation investment.
Beyond DAYBUE, Neuren’s second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders. Positive results have been achieved in Phase 2 clinical trials for Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Each programme has been granted orphan drug designation in both the United States and European Union.
The investment thesis combines:
- DAYBUE royalty income scaling with Acadia’s sales growth trajectory through 2028 and beyond
- Geographic expansion providing revenue diversification as Europe, Israel and Japan contribute to global sales
- NNZ-2591 pipeline offering additional value creation opportunities across multiple rare disease indications with distinct patient populations
The DAYBUE sales projections provide visibility on near-term revenue growth, whilst the NNZ-2591 pipeline represents optionality for longer-term value creation. The orphan drug designations across both programmes provide regulatory advantages and market exclusivity periods that protect commercial positioning.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
Real-World Evidence and Market Momentum
Acadia’s real-world LOTUS study has enrolled over 300 patients, generating data that supports broader clinical adoption and reimbursement discussions. The study continues to develop and publish findings that validate DAYBUE’s therapeutic benefit in real-world settings beyond controlled clinical trials.
The 12-month persistency rate reaching 55% represents an improving trend, indicating patient and physician satisfaction with treatment outcomes. This metric is critical for sustained revenue growth, as persistency directly influences the durability of Acadia’s revenue base and, consequently, Neuren’s royalty income.
Persistency above 50% at the 12-month mark suggests that more than half of patients initiating therapy continue treatment for at least one year. This retention rate supports formulary positioning and reimbursement negotiations, as payers evaluate long-term treatment adherence when making coverage decisions.
The continued generation of real-world data strengthens DAYBUE’s commercial positioning against potential future competitors. As the first and only approved therapy, DAYBUE benefits from accumulating clinical experience and published outcomes data that new entrants would need to match or exceed.
Stay ahead with Biotech breakthroughs
Join over 20,000 investors already receiving the free Big News Blasts from StockWire X. These alerts deliver breaking biotech news and in-depth analysis focused exclusively on the ASX’s non-resource sectors, helping subscribers act promptly on key developments like innovative therapies and market-moving clinical data.
Don’t miss your chance to deepen your insight and track emerging opportunities—simply click the “Free Alerts” button in the site header to sign up for StockWire X’s Big News Blasts today.